Mastectomy, Segmental

2

Review clinical trials related to Mastectomy, Segmental. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Acellular Dermal Matrix(SureDerm BCS) in Breast-Conserving Surgery for Breast Cancer Patients

The goal of this clinical trial is to evaluate whether the use of an acellular dermal matrix (SureDerm) can improve cosmetic satisfaction and is safe in women with breast cancer undergoing breast-conserving surgery. The main questions it aims to answer are: 1. Does the use of SureDerm improve patient-reported cosmetic satisfaction after breast-conserving surgery? 2. Is the use of SureDerm safe in terms of complication rates compared to standard surgery without SureDerm? Researchers will compare patients receiving SureDerm during surgery with patients undergoing standard breast-conserving surgery without SureDerm to see if cosmetic results and safety differ between the groups. Participants will: * Undergo breast-conserving surgery, with or without SureDerm (assigned randomly) * Receive standard postoperative radiotherapy * Complete questionnaires about cosmetic satisfaction (Breast-Q) at baseline, 1 month, and 12 months after surgery * Be followed for complications and cosmetic assessments by physicians

Participants needed: 116
Trial details
Age: 20-75Biological sex: FemaleType: InterventionalSponsor: Seoul St. Mary's HospitalUpdated: Jan 15, 2026Locations: 1
Eligibility criteria

Female patients aged 20 to 75 years [+6]

Evidence of distant metastasis [+10]

Status: Recruiting

Safety and Performance of REGENERA Breast Implant in Women Affected by Malignant Breast Lesion Treated by Lumpectomy

The goals of this clinical trial are: * demonstrate the safety of REGENERA breast implant in patients undergoing lumpectomy of malignant breast lesions * demonstrate the safety and performance of REGENERA in terms of investigator's satisfaction, potential interference with current standard-of-care imaging techniques and occurrence of device-related serious adverse events.

Participants needed: 92
Trial details
Age: 40-70Biological sex: FemaleType: InterventionalSponsor: Tensive SRLUpdated: Nov 22, 2024Locations: 3
Eligibility criteria

Female adult subject aged 40-70 years. [+11]

Subject with actual concomitant benign breast lesion (B2 and B3), unless present... [+19]